标题
Use of SGLT2 Inhibitors in Older Adults: Scientific Evidence and Practical Aspects
作者
关键词
-
出版物
DRUGS & AGING
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2020-04-01
DOI
10.1007/s40266-020-00757-y
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Inhibition of the sodium-glucose co-transporter 2 in the elderly: clinical and mechanistic insights into safety and efficacy
- (2019) Riobaldo Cintra et al. Revista da Associacao Medica Brasileira
- Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline
- (2019) Derek LeRoith et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM – 2019 EXECUTIVE SUMMARY
- (2019) Alan J. Garber et al. Endocrine Practice
- The Dapagliflozin And Prevention of Adverse‐outcomes in Heart Failure (DAPA‐HF) trial: baseline characteristics
- (2019) John J.V. McMurray et al. EUROPEAN JOURNAL OF HEART FAILURE
- 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
- (2019) Francesco Cosentino et al. EUROPEAN HEART JOURNAL
- Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial
- (2019) Ofri Mosenzon et al. Lancet Diabetes & Endocrinology
- Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial
- (2019) Pedro Monteiro et al. AGE AND AGEING
- Potential Mechanisms of Sodium-Glucose Co-Transporter 2 Inhibitor-Related Cardiovascular Benefits
- (2019) Subodh Verma AMERICAN JOURNAL OF CARDIOLOGY
- Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE–TIMI 58 Study
- (2019) Avivit Cahn et al. DIABETES CARE
- SGLT2 inhibition and heart failure—current concepts
- (2018) Joaquim Silva Custodio et al. HEART FAILURE REVIEWS
- Management of diabetes in older adults
- (2018) G. Sesti et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- 12. Older Adults: Standards of Medical Care in Diabetes—2019
- (2018) DIABETES CARE
- Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2018) Melanie J. Davies et al. DIABETES CARE
- Pump, pipes, and filter: do SGLT2 inhibitors cover it all?
- (2018) Subodh Verma et al. LANCET
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2018) Thomas A Zelniker et al. LANCET
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- New pharmacological strategies for protecting kidney function in type 2 diabetes
- (2018) Marcel H A Muskiet et al. Lancet Diabetes & Endocrinology
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nrf2 signaling and redox homeostasis in the aging heart: A potential target to prevent cardiovascular diseases?
- (2016) Alejandro Silva-Palacios et al. AGEING RESEARCH REVIEWS
- Diabetes and Frailty: Two Converging Conditions?
- (2016) Alan J. Sinclair et al. Canadian Journal of Diabetes
- The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitus
- (2016) Maria Alba et al. CURRENT MEDICAL RESEARCH AND OPINION
- Long-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III Studies
- (2016) Paola Fioretto et al. DRUGS & AGING
- AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS
- (2016) Yehuda Handelsman et al. Endocrine Practice
- Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin
- (2016) John P. Bilezikian et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus
- (2016) Nelson B. Watts et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Efficacy and Safety of Canagliflozin in Individuals Aged 75 and Older with Type 2 Diabetes Mellitus: A Pooled Analysis
- (2016) Alan J. Sinclair et al. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
- Renal, metabolic and cardiovascular considerations of SGLT2 inhibition
- (2016) Ralph A. DeFronzo et al. Nature Reviews Nephrology
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Osmotic diuresis with SGLT2 inhibition: analysis of events related to volume reduction in dapagliflozin clinical trials
- (2016) Kristina Johnsson et al. POSTGRADUATE MEDICINE
- Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin–angiotensin system blockade
- (2015) Michael A. Weber et al. BLOOD PRESSURE
- Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors
- (2015) Julio Rosenstock et al. DIABETES CARE
- Association of Cardiometabolic Multimorbidity With Mortality
- (2015) Emanuele Di Angelantonio et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
- (2015) Jennifer B. Green et al. NEW ENGLAND JOURNAL OF MEDICINE
- The aging kidney revisited: A systematic review
- (2014) Davide Bolignano et al. AGEING RESEARCH REVIEWS
- State of the art paper Heart failure in the diabetic population – pathophysiology, diagnosis and management
- (2014) Jacek Kasznicki et al. Archives of Medical Science
- Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
- (2013) David Z.I. Cherney et al. CIRCULATION
- Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin
- (2013) J. Bolinder et al. DIABETES OBESITY & METABOLISM
- Metabolic dysfunction in diabetic cardiomyopathy
- (2013) Michael Isfort et al. HEART FAILURE REVIEWS
- Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
- (2013) William B. White et al. NEW ENGLAND JOURNAL OF MEDICINE
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- SGLT inhibitors in management of diabetes
- (2013) Abd A Tahrani et al. Lancet Diabetes & Endocrinology
- Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin
- (2012) Ö. Ljunggren et al. DIABETES OBESITY & METABOLISM
- Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin
- (2012) Jan Bolinder et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- A simple frailty questionnaire (FRAIL) predicts outcomes in middle aged African Americans
- (2012) John E. Morley et al. Journal of Nutrition Health & Aging
- Impact of the U.S. Food and Drug Administration Cardiovascular Assessment Requirements on the Development of Novel Antidiabetes Drugs
- (2011) B. Hirshberg et al. DIABETES CARE
- Acute Kidney Injury in the Elderly
- (2009) Khaled Abdel-Kader et al. CLINICS IN GERIATRIC MEDICINE
- From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
- (2009) R. A. DeFronzo DIABETES
- The Hemoglobin A1c Level as a Progressive Risk Factor for Cardiovascular Death, Hospitalization for Heart Failure, or Death in Patients With Chronic Heart Failure
- (2008) Hertzel C. Gerstein ARCHIVES OF INTERNAL MEDICINE
- Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes
- (2008) Peter Gæde et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started